Backed by robust preclinical data, RES-010 is currently being evaluated in a Phase 1 clinical trial, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
Members of our management team will be at:
1st Annual BioPharma Obesity Innovation Forum 2025
January 11, San Francisco
JPM Healthcare Conference 2025
January 13-16, San Francisco
